Discovery of novel [1,2,4]triazolo[4,3-a]quinoxaline aminophenyl derivatives as BET inhibitors for cancer treatment.

Bromodomain and extra-terminal (BET) proteins, a class of epigenetic reader domains has emerged as a promising new target class for small molecule drug discovery for the treatment of cancer, inflammatory, and autoimmune diseases. Starting from in silico screening campaign, herein we report the discovery of novel BET inhibitors based on [1,2,4]triazolo[4,3-a]quinoxaline scaffold and their biological evaluation. The hit compound was optimized using the medicinal chemistry approach to the lead compound with excellent inhibitory activities against BRD4 in the binding assay. The substantial antiproliferative activities in human cancer cell lines, promising drug-like properties, and the selectivity for the BET family make the lead compound (13) as a novel BRD4 inhibitor motif for anti-cancer drug discovery.

[1]  Kathryn A. Giblin,et al.  The structure based design of dual HDAC/BET inhibitors as novel epigenetic probes , 2014 .

[2]  A. Belkina,et al.  BET domain co-regulators in obesity, inflammation and cancer , 2012, Nature Reviews Cancer.

[3]  A. Gingras,et al.  Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family , 2012, Cell.

[4]  A. Brasier,et al.  Drug Discovery Targeting Bromodomain-Containing Protein 4 , 2017, Journal of medicinal chemistry.

[5]  Christopher J. Ott,et al.  BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. , 2012, Blood.

[6]  Yan Zhang,et al.  Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation. , 2016, Journal of medicinal chemistry.

[7]  Nathan Brown,et al.  Druggability Analysis and Structural Classification of Bromodomain Acetyl-lysine Binding Sites , 2012, Journal of medicinal chemistry.

[8]  S. Lowe,et al.  RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia , 2011, Nature.

[9]  Jeroen Krijgsveld,et al.  Cooperative binding of two acetylation marks on a histone tail by a single bromodomain , 2009, Nature.

[10]  S. Robson,et al.  Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia , 2011, Nature.

[11]  Saptarsi M. Haldar,et al.  BET Bromodomains Mediate Transcriptional Pause Release in Heart Failure , 2013, Cell.

[12]  S. Knapp,et al.  The therapeutic potential of acetyl-lysine and methyl-lysine effector domains , 2012 .

[13]  Gunda I Georg,et al.  BET Bromodomain Inhibitors with One-Step Synthesis Discovered from Virtual Screen. , 2017, Journal of medicinal chemistry.

[14]  C. Bountra,et al.  Epigenetic protein families: a new frontier for drug discovery , 2012, Nature Reviews Drug Discovery.

[15]  Christopher W Murray,et al.  Fragment-based lead discovery: leads by design. , 2005, Drug discovery today.

[16]  Brian K. Shoichet,et al.  ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..

[17]  C. Rice,et al.  Suppression of inflammation by a synthetic histone mimic , 2010, Nature.

[18]  P. Sandy,et al.  Targeting MYC dependence in cancer by inhibiting BET bromodomains , 2011, Proceedings of the National Academy of Sciences.

[19]  David M. Wilson,et al.  Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A). , 2012, Bioorganic & medicinal chemistry letters.

[20]  P. Bamborough,et al.  Discovery and characterization of small molecule inhibitors of the BET family bromodomains. , 2011, Journal of medicinal chemistry.

[21]  W. Delano.  The PyMOL Molecular Graphics System , 2002 .

[22]  P. P. Sharp,et al.  BET bromodomain inhibitors: a patent review , 2014, Expert opinion on therapeutic patents.

[23]  C. Chung,et al.  Bromodomains: a new target class for small molecule drug discovery , 2012 .

[24]  S. Knapp,et al.  Discovery of BET bromodomain inhibitors and their role in target validation , 2014 .

[25]  C. Petosa,et al.  Bromodomains: Structure, function and pharmacology of inhibition. , 2016, Biochemical pharmacology.

[26]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.